Chronic Heart Failure: PBAC Recommends Empagliflozin

By Staff Writer

April 14, 2023

Introduction:

The Pharmaceutical Benefits Scheme (PBS) included Empagliflozin, a sodium glucose co transporter 2 (SGLT2) inhibitor, for chronic heart failure (CHF) treatment with reduced ejection fraction (LVEF ≤40%) starting April 1, 2022. Yet, the Pharmaceutical Benefits Advisory Committee (PBAC) decided in November 2022 not to endorse Empagliflozin for treating CHF in patients with a left ventricular ejection fraction over 40%. They based their decision on the high unmet clinical need and the economic model’s failure to capture the disease’s progressive nature adequately. A price reduction and risk sharing arrangement were required.

The PBAC has recommended an extension to the current empagliflozin listing on an updated addendum. This extension will include a General Schedule Authority Required (Streamlined) listing. It will be for the treatment of chronic heart failure in patients. These patients have a left ventricular ejection fraction greater than 40%. This recommendation comes after the sponsor addressed the outstanding issues. Also, the cost-effectiveness of the treatment is acceptable at the proposed price.

Empagliflozin’s Efficacy:

The PBAC observed a significant improvement in efficacy when adding Empagliflozin to standard care for this patient group. They based this observation on the primary composite outcome in EMPEROR-Preserved studies. These studies measured the time to the first cardiovascular death or hospitalisation for heart failure.

Addressing Outstanding Issues:

In conclusion, the sponsor has addressed significant outstanding issues identified in the November 2022 PBAC meeting. This was achieved through a proposed price reduction and risk sharing arrangement. The PBAC’s recommendation for listing was based on its assessment that the cost-effectiveness of Empagliflozin would be acceptable at the revised offer price of 16 December 2022.

Reference url

Recent Posts

Argentina WHO Withdrawal
   

Argentina WHO Withdrawal: President Milei Exits Global Health Alliance Amid COVID-19 Disputes

💡 *What happens when a country decides to withdraw from global health organizations?*
Argentina’s President Javier Milei has made the bold move to withdraw from the WHO, citing significant disagreements over health management during the pandemic. This decision raises questions about national sovereignty, cooperation, and the future of global health initiatives. Dive into the implications of Argentina’s stance and what it means for international health governance.

#SyenzaNews #globalhealth #healthcarepolicy

Gauteng HPV vaccination campaign
      

Gauteng HPV Vaccination Campaign: Protecting Girls Against Cervical Cancer

💉 Ready to protect our future generations from cervical cancer?

The Gauteng HPV vaccination campaign aims to vaccinate grade 5, 6, and 7 girls against the virus that causes most cervical cancers. By leveraging a single-dose regimen, this initiative not only enhances access to life-saving vaccines but also strives to meet ambitious global health targets.

Explore how this campaign is reshaping health outcomes in South Africa and why parental consent is key to its success.

#SyenzaNews #HealthEconomics #HealthcareInnovation #UniversalHealthCoverage

Capvaxive vaccine approval
     

Capvaxive Vaccine Approval

🌍 What if a single vaccine could significantly change the landscape of pneumococcal disease prevention in adults?

The European Medicines Agency has just recommended Merck’s Capvaxive, an innovative 21-valent pneumococcal conjugate vaccine! With robust data from multiple phase 3 trials, this potential approval marks a pivotal step in the fight against invasive Streptococcus pneumoniae infections in the EU. Look into how Capvaxive could enhance public health outcomes and offer extensive serotype coverage.

#SyenzaNews #pharmaceuticals #healthcarepolicy

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.